Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 482

1.

Parkinson's disease: Is it a consequence of human brain evolution?

Diederich NJ, James Surmeier D, Uchihara T, Grillner S, Goetz CG.

Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27628. [Epub ahead of print] No abstract available.

PMID:
30759321
2.

Telemedicine vs Office Visits in a Movement Disorders Clinic: Comparative Satisfaction of Physicians and Patients.

Hanson RE, Truesdell M, Stebbins GT, Weathers AL, Goetz CG.

Mov Disord Clin Pract. 2018 Dec 13;6(1):65-69. doi: 10.1002/mdc3.12703. eCollection 2019 Jan.

PMID:
30746418
3.

Missing Data in the Unified Dysksinesia Rating Scale (UDysRS).

Luo S, Ren X, Han W, Goetz CG, Stebbins GT.

Mov Disord Clin Pract. 2018 Aug 24;5(5):523-526. doi: 10.1002/mdc3.12642. eCollection 2018 Sep-Oct.

PMID:
30515442
4.

Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations.

Pavy-Le Traon A, Cotterill N, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Rascol O, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Oct 25;5(5):479-491. doi: 10.1002/mdc3.12636. eCollection 2018 Sep-Oct. Review.

PMID:
30515437
5.

Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Mestre TA, Busse M, Davis AM, Quinn L, Rodrigues FB, Burgunder JM, Carlozzi NE, Walker F, Ho AK, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 May 9;5(4):361-372. doi: 10.1002/mdc3.12617. eCollection 2018 Jul-Aug.

PMID:
30363510
6.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the Movement Disorder Society Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.

7.

Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale.

Akbostanci MC, Bayram E, Yilmaz V, Rzayev S, Özkan S, Tokcaer AB, Saka E, Durmaz Celik FN, Barut BÖ, Tüfekcioglu Z, Acarer A, Balaban H, Erer S, Dogu O, Kibaroglu S, Aydin N, Hanagasi H, Elibol B, Emre M, Stebbins GT, Goetz CG.

Mov Disord Clin Pract. 2017 Nov 16;5(1):54-59. doi: 10.1002/mdc3.12556. eCollection 2018 Jan-Feb.

8.

Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Skorvanek M, Martinez-Martin P, Stebbins GT, Goetz CG.

Mov Disord. 2018 Jul;33(7):1189-1190. doi: 10.1002/mds.27452. No abstract available.

PMID:
30153386
9.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
10.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.

PMID:
30145797
11.

What influences placebo and nocebo responses in Parkinson's disease?

Witek N, Stebbins GT, Goetz CG.

Mov Disord. 2018 Aug;33(8):1204-1212. doi: 10.1002/mds.27416. Epub 2018 Aug 22. Review.

PMID:
30132980
12.

Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients.

Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Valkovic P, Goetz CG, Stebbins GT.

Parkinsonism Relat Disord. 2018 Jul;52:83-89. doi: 10.1016/j.parkreldis.2018.03.027. Epub 2018 Mar 28.

PMID:
29625875
13.

Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life.

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 May;33(5):742-749. doi: 10.1002/mds.27317. Epub 2018 Mar 23. Review.

PMID:
29570848
14.

Telemedicine Use for Movement Disorders: A Global Survey.

Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, Mari Z, Pantelyat A, Galifianakis NB, Bajwa JA, Gatto EM, Cubo E.

Telemed J E Health. 2018 Dec;24(12):979-992. doi: 10.1089/tmj.2017.0295. Epub 2018 Mar 22.

PMID:
29565764
15.

Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P.

Mov Disord. 2018 Mar;33(3):499-500. doi: 10.1002/mds.27339. Epub 2018 Feb 20. No abstract available.

PMID:
29460975
16.

Validation study of the hoehn and yahr scale included in the MDS-UPDRS.

Martinez-Martin P, Skorvanek M, Rojo-Abuin JM, Gregova Z, Stebbins GT, Goetz CG; members of the QUALPD Study Group.

Mov Disord. 2018 Apr;33(4):651-652. doi: 10.1002/mds.27242. Epub 2018 Jan 11. No abstract available.

PMID:
29322548
17.

Rating scales for cognition in Huntington's disease: Critique and recommendations.

Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 Feb;33(2):187-195. doi: 10.1002/mds.27227. Epub 2017 Dec 26. Review.

PMID:
29278291
18.

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P; members of the MDS Rating Scales Review Committee.

Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23. Review.

PMID:
29168899
19.

Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?

Goetz CG.

Mov Disord. 2017 Dec;32(12):1651-1652. doi: 10.1002/mds.27214. Epub 2017 Nov 9. No abstract available.

PMID:
29119602
20.

Does Added Objective Tremor Monitoring Improve Clinical Outcomes in Essential Tremor Treatment?

Vittal P, Pulliam CL, Goetz CG, Ouyang B, Jankovic J, Ramirez-Castaneda JL, Heldman DA.

Mov Disord Clin Pract. 2017 Oct 25;5(1):96-98. doi: 10.1002/mdc3.12554. eCollection 2018 Jan-Feb. No abstract available.

21.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

22.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

23.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.

Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA.

Mov Disord. 2017 Sep;32(9):1335-1336. doi: 10.1002/mds.27092. Epub 2017 Jun 24. No abstract available.

PMID:
28646494
24.

Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS).

Luo S, Liu Y, Teresi JA, Stebbins GT, Goetz CG.

Mov Disord. 2017 Aug;32(8):1244-1249. doi: 10.1002/mds.27058. Epub 2017 Jun 1.

25.

Charcot: Past and present.

Goetz CG.

Rev Neurol (Paris). 2017 Dec;173(10):628-636. doi: 10.1016/j.neurol.2017.04.004. Epub 2017 May 10. Review. French.

PMID:
28501142
26.

Dramatic science or scientific drama?

Goetz CG.

Brain. 2017 Apr 27. doi: 10.1093/brain/awx097. [Epub ahead of print] No abstract available.

PMID:
28453781
27.

Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society- Unified Parkinson's Disease Rating Scale.

Yu RL, Wu RM, Chan AY, Mok V, Wu YR, Tilley BC, Luo S, Wang L, LaPelle NR, Stebbins GT, Goetz CG.

Mov Disord Clin Pract. 2017 Jan-Feb;4(1):68-77. doi: 10.1002/mdc3.12349. Epub 2016 Apr 8.

28.

Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Foltynie T, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Aviles-Olmos I, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Huang J, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Tilley BC, Valkovic P, Goetz CG, Stebbins GT.

Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.

29.

Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations".

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):482. doi: 10.1002/mds.26954. Epub 2017 Mar 3. No abstract available.

PMID:
28256103
30.

Systematic review of severity scales and screening instruments for tics: Critique and recommendations.

Martino D, Pringsheim TM, Cavanna AE, Colosimo C, Hartmann A, Leckman JF, Luo S, Munchau A, Goetz CG, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):467-473. doi: 10.1002/mds.26891. Epub 2017 Jan 10. Review.

31.

Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.

Goetz CG, Liu Y, Stebbins GT, Wang L, Tilley BC, Teresi JA, Merkitch D, Luo S.

Mov Disord. 2016 Dec;31(12):1865-1873. doi: 10.1002/mds.26847. Epub 2016 Nov 7.

32.

Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.

Kordower JH, Goetz CG, Chu Y, Halliday GM, Nicholson DA, Musial TF, Marmion DJ, Stoessl AJ, Sossi V, Freeman TB, Olanow CW.

Ann Neurol. 2017 Jan;81(1):46-57. doi: 10.1002/ana.24820. Epub 2017 Jan 6.

33.

Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease.

Bernard BA, Metman LV, Levine L, Ouyang B, Leurgans S, Goetz CG.

Mov Disord Clin Pract. 2016 Nov 20;4(3):412-415. doi: 10.1002/mdc3.12456. eCollection 2017 May-Jun.

34.

Charcot, hysteria, and simulated disorders.

Goetz CG.

Handb Clin Neurol. 2016;139:11-23. doi: 10.1016/B978-0-12-801772-2.00002-3. Review.

PMID:
27719832
35.

Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease.

Pal GD, Hall D, Ouyang B, Phelps J, Alcalay R, Pauciulo MW, Nichols WC, Clark L, Mejia-Santana H, Blasucci L, Goetz CG, Comella C, Colcher A, Gan-Or Z, Rouleau GA, Marder K; Consortium on Risk for Early Onset Parkinson's Disease (CORE-PD) Investigators.

Mov Disord Clin Pract. 2016 Sep-Oct;3(5):465-471. Epub 2016 Jan 18.

36.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
37.

Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations.

Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodríguez-Blázquez C, Chaudhuri KR, Deuschl G, Cruccu G, Sampaio C, Goetz CG, Schrag A, Martinez-Martin P, Stebbins G; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2016 Jun 24;3(6):527-537. doi: 10.1002/mdc3.12384. eCollection 2016 Nov-Dec.

38.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
39.

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2016 Oct;31(10):1466-1478. doi: 10.1002/mds.26675. Review.

PMID:
27296904
40.

Fatigue in Parkinson's disease: report from a mutidisciplinary symposium.

Friedman JH, Beck JC, Chou KL, Clark G, Fagundes CP, Goetz CG, Herlofson K, Kluger B, Krupp LB, Lang AE, Lou JS, Marsh L, Newbould A, Weintraub D.

NPJ Parkinsons Dis. 2016;2. pii: 15025. Epub 2016 Jan 14.

41.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
42.

Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.

Shulman LM, Armstrong M, Ellis T, Gruber-Baldini A, Horak F, Nieuwboer A, Parashos S, Post B, Rogers M, Siderowf A, Goetz CG, Schrag A, Stebbins GT, Martinez-Martin P.

Mov Disord. 2016 Oct;31(10):1455-1465. doi: 10.1002/mds.26649. Review.

PMID:
27193358
43.

Clinimetric testing of the comprehensive cervical dystonia rating scale.

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT.

Mov Disord. 2016 Apr;31(4):563-9. doi: 10.1002/mds.26534. Epub 2016 Mar 12.

44.

Parkinson's disease-related fatigue: A case definition and recommendations for clinical research.

Kluger BM, Herlofson K, Chou KL, Lou JS, Goetz CG, Lang AE, Weintraub D, Friedman J.

Mov Disord. 2016 May;31(5):625-31. doi: 10.1002/mds.26511. Epub 2016 Feb 16. Review.

45.

Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease.

Diederich NJ, Goldman JG, Stebbins GT, Goetz CG.

Mov Disord. 2016 Jan;31(1):11-22. doi: 10.1002/mds.26460. Epub 2015 Dec 9. Review.

PMID:
26650182
46.

MDS research criteria for prodromal Parkinson's disease.

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G.

Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431. Review.

PMID:
26474317
47.

MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. Review.

PMID:
26474316
48.

Preface.

Poewe W, Goetz CG.

Mov Disord. 2015 Sep 15;30(11):1441. doi: 10.1002/mds.26385. Epub 2015 Aug 24. No abstract available.

PMID:
26301896
49.

The Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD): Tolerability of Preoperative Neuropsychological Testing for Deep Brain Stimulation in Parkinson's Disease.

Pal GD, Persinger V, Bernard B, Ouyang B, Goetz CG, Verhagen Metman L.

Mov Disord Clin Pract. 2015 Jul 14;2(4):379-383. doi: 10.1002/mdc3.12213. eCollection 2015 Dec.

50.

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.

Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE.

Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436. Epub 2015 Jun 10.

PMID:
26061140

Supplemental Content

Loading ...
Support Center